Avycaz May Be Effective for Multidrug-resistant P. aeruginosa Infections in CF Patients, Study Sugge
Antibacterial Avycaz (ceftazidime-avibactam) showed significant in vitroefficacy against multidrug-resistant Pseudomonas aeruginosa...
Ultrasound Predicts Advanced Liver Disease in CF Patients, According to Clinical Trial Data
Ultrasound may predict liver disease in young cystic fibrosis (CF) patients, according to the results of a clinical trial. Researchers...
New cystic fibrosis drugs significantly improve lung function
A triple drug combination for treating the underlying cause of cystic fibrosis is currently under study. The preliminary results show a...
Law Student returned to life with lung transplantation
Law student came back to life with lung transplantation, 20 years of law student struggles with genetic disease ISTANBUL – For many...
The Bittersweet Downside of CFTR Modulators
I’ve been on Orkambi (lumacaftor/ivacaftor), a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, for just over three...
#NACFC2018 – RPL554 Shows Promising Results in CF Studies
Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented...
Worse CF Lung Outcomes Linked with Mutations Causing Iron Overload Disorder, Study Finds
Patients with cystic fibrosis (CF) who carry certain mutations in the HFE gene, which are also behind an iron overload disorder, have...
Cystic Fibrosis Lung Function Improved With Triple Therapy
Patients with cystic fibrosis with either 1 or 2 Phe508del alleles who were treated with a drug combination of VX-659, tezacaftor, and...
Mucus, cough and chronic lung disease: New discoveries
As a cold ends, a severe mucus cough starts. Sound familiar? Two studies now give explanations: First, crucial mechanisms of the mucus in...
AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study
On track to initiate Phase 2 trial in cystic fibrosis patients in the fourth quarter of 2018 and conclude in 2019 NEW YORK, Nov. 01, 2018...
